This edition has been authored by physician-scientist and global biotechnology leader Jeremy Levin, who is also a Scrip Lifetime Achievement Award winner.
Pharmaceutical companies have always looked beyond their own labs for new medicines. Acquisitions and partnerships have strengthened pipelines, created value and brought important treatments to patients. I have spent much of my career leading such strategic decisions. At Bristol-Myers Squibb, the ‘String of Pearls’ strategy emerged from an urgent need to reconstruct a company whose pipeline could no longer sustain its future.
We needed a new scientific direction, which meant investing in biologics, withdrawing from less productive areas, and using external innovation to help transform the business. These were deliberate strategic choices, not simply transactions to add products. Yet the experience also taught me that rebuilding a pipeline and establishing the ability to renew it repeatedly are not necessarily the same achievement.
Today, the expanding international supply of promising molecules presents pharmaceutical companies with opportunities that were far less accessible a generation ago. Faced with patent expirations and the need to replenish revenues, they can acquire assets that have already passed important development milestones. Such transactions may offer greater visibility into clinical prospects, remaining development costs, and commercial potential than investments in unproven discovery programs. They can be entirely rational uses of shareholders' capital.